Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 8, 2015, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $360.00 to $2,410,815.00.

Highlighted Stocks Traded by Insiders:

ABM Industries (ABM) - FREE Research Report

Price Tracy K, who is Executive Vice President at ABM Industries, sold 4,426 shares at $32.15 on July 8, 2015. Following this transaction, the Executive Vice President owned 72,793 shares meaning that the stake was reduced by 5.73% with the 4,426-share transaction.

The shares most recently traded at $32.31, up $0.16, or 0.5% since the insider transaction. Historical insider transactions for ABM Industries go as follows:

  • 4-Week # shares sold: 10,675
  • 12-Week # shares sold: 20,675
  • 24-Week # shares sold: 37,932

The average volume for ABM Industries has been 235,200 shares per day over the past 30 days. ABM Industries has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are up 11.76% year-to-date as of the close of trading on Wednesday.

ABM Industries Incorporated provides integrated facility solutions services in the United States and internationally. The stock currently has a dividend yield of 1.99%. The company has a P/E ratio of 21.5. Currently, there are 3 analysts who rate ABM Industries a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABM - FREE

TheStreet Quant Ratings

rates ABM Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

ABM Industries Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Century Bancorp (CNBKA) - FREE Research Report

Filler James J, who is 10% Owner at Century Bancorp, bought 536 shares at $39.80 on July 8, 2015. Following this transaction, the 10% Owner owned 421,394 shares meaning that the stake was boosted by 0.13% with the 536-share transaction.

The shares most recently traded at $40.17, up $0.37, or 0.92% since the insider transaction. Historical insider transactions for Century Bancorp go as follows:

  • 4-Week # shares bought: 7,802
  • 12-Week # shares bought: 19,071
  • 24-Week # shares bought: 30,449

The average volume for Century Bancorp has been 4,300 shares per day over the past 30 days. Century Bancorp has a market cap of $144.0 million and is part of the financial sector and banking industry. Shares are down 0.65% year-to-date as of the close of trading on Wednesday.

Century Bancorp, Inc. operates as the bank holding company for Century Bank and Trust Company that provides banking products and services to commercial enterprises, state and local governments and agencies, nonprofit organizations, and individuals in Massachusetts. The stock currently has a dividend yield of 1.2%. The company has a P/E ratio of 10.2.

Exclusive Offer: Get the latest Stock Analysis on CNBKA - FREE

TheStreet Quant Ratings

rates Century Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Century Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cell Therapeutics (CTIC) - FREE Research Report

Plunkett Matthew, who is EVP, Corporate Development at Cell Therapeutics, sold 10,000 shares at $1.95 on July 8, 2015. Following this transaction, the EVP, Corporate Development owned 681,740 shares meaning that the stake was reduced by 1.45% with the 10,000-share transaction.

The shares most recently traded at $3.01, up $1.06, or 35.24% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 95,000
  • 24-Week # shares sold: 525,498

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.